With the availability of genome-wide data describing de novo mutations in human cardiovascular disease, these large data sets could be surveyed for MEF2 mutations and, with current gene editing tools such as CRISPR/Cas9, specific mutations engineered in the MEF2 genes to assess phenotypic effects in vivo. This evidence concerns the gene MEF2A and cardiovascular disorder.